PDRN Skincare 2026: What the New Topical Trials Show

Q: What is PDRN in skincare?

Polydeoxyribonucleotide — DNA fragments of roughly 50 to 1,500 kDa purified from salmon trout or chum salmon sperm DNA, with proteins and peptides removed. Its proposed mechanism is engaging the adenosine A2A receptor and supplying nucleotides to the cellular salvage pathway.

Q: Does topical PDRN actually work?

Two specific preparations now have published human data. A December 2025 study of low-molecular-weight peony PDRN reported improved periorbital elasticity after four weeks, and a July 2026 randomised split-face trial found a 0.1% medium-length PDRN eye cream beat an identical 0.1% retinol cream on dermal thickness and crow's feet over 28 days. Neither result transfers automatically to an unspecified salmon-derived serum.

Q: Is PDRN the same as salmon DNA?

Effectively yes as source material. PDRN is purified, fragmented DNA from salmon trout or chum salmon sperm. "Salmon DNA skincare" is the consumer-facing name, though it also gets applied to products containing related polynucleotides rather than PDRN specifically.

Q: PDRN or polynucleotides — what's the difference?

They are related and brands use the terms interchangeably, but polynucleotide generally refers to longer-chain material while PDRN denotes the specific fragmented, purified preparation described in the pharmacology literature.

Q: How do I tell if a PDRN serum is legitimate?

Check whether it says PDRN or PN, whether a concentration is stated, where the ingredient sits in the INCI list, and whether the brand states a molecular weight. That last one matters most — the two preparations with published topical human data are a low-MW plant-derived PDRN and a medium-length one capped at 850 kDa.

Q: Should I get PDRN injections instead?

That is a physician question, and the answer depends on your skin, your goals and what is legally available where you are — regulatory status varies sharply by country. Discuss it with a doctor rather than deciding from an article.

Direct Answer

PDRN is polydeoxyribonucleotide — DNA fragments of roughly 50 to 1,500 kDa purified from salmon trout or chum salmon sperm DNA, thought to act by engaging the adenosine A2A receptor and feeding the cellular salvage pathway. Its foundational clinical evidence is as an injected drug for wound healing, notably diabetic foot ulcers, and a 2025 systematic review of injectable aesthetic use found nine studies covering 219 patients at low-to-moderate evidence quality.

That changed in late 2025. A December 2025 study of low-molecular-weight Paeonia lactiflora PDRN reported improved periorbital elasticity after four weeks of topical use, and a July 2026 randomised, double-blind, split-face trial in PLOS ONE found a 0.1% medium-length PDRN eye cream outperformed an identically formulated 0.1% retinol cream on dermal thickness and crow's feet over 28 days — with penetration separately measured. So topical PDRN is no longer evidence-free. But the evidence attaches to a specific molecular weight, source, concentration and formula, not to the four letters on the box. Ask which preparation.

1. What PDRN actually is

PDRN stands for polydeoxyribonucleotide: a mixture of DNA fragments with molecular weights between roughly 50 and 1,500 kDa, purified from the sperm DNA of salmon trout (Oncorhynchus mykiss) or chum salmon (Oncorhynchus keta). The purification process is designed to remove proteins and peptides that could provoke an immune reaction.

The proposed mechanism has two parts. PDRN engages the adenosine A2A receptor, which is where its anti-inflammatory and tissue-repair signalling is thought to originate. It also supplies nucleosides and nucleotides to what is called the salvage pathway — effectively handing cells pre-made building blocks rather than making them synthesise their own.

The thing to understand before anything else: PDRN entered medicine as an injectable drug for wound healing, and that is where its evidence lives. The published clinical work is on diabetic foot ulcers, post-surgical healing and similar indications — injected or infiltrated, in patients, under supervision. A serum you rub on your face is a different product making a different bet.

2. Topical and injectable are not the same product

This is the distinction the marketing collapses, and it is the whole article.

Two Different Things Sharing One Name

	Injectable PDRN / polynucleotides	Topical PDRN skincare
What it is	A regulated drug in the markets where it is approved	A cosmetic ingredient in a serum, cream or mask
Delivery	Placed into the dermis directly	Applied to the stratum corneum and has to cross it
Evidence base	Published clinical trials, mostly wound healing	Thin. Mostly manufacturer studies and in-vitro work
Who administers	A physician	You, at your bathroom sink
Regulatory status	Varies sharply by country	Cosmetic in most markets

The molecular-weight problem is the honest objection — but it is not permanent. Salmon-derived PDRN is by definition a large molecule (50 to 1,500 kDa), and the intact skin barrier excludes molecules far smaller than that. So any topical product using standard PDRN is making an unstated claim that a meaningful quantity crosses into living tissue. What has changed since 2025 is that formulators started attacking the problem directly — lower-molecular-weight plant-derived PDRN, and medium-length preparations with published penetration work behind them. The question is no longer "can PDRN ever get in" but "does this preparation, at this molecular weight, in this formula."

3. What the evidence does and does not show

The foundational reference is a 2017 mini-review in Frontiers in Pharmacology by Squadrito and colleagues at the University of Messina. It remains the standard summary of PDRN's pharmacology — and reading it carefully is instructive, because it is a review of a drug, not of a serum.

For the injectable side, the useful reference is a systematic review by Lampridou and colleagues in the Journal of Cosmetic Dermatology. It found nine aesthetic studies covering 219 patients, published between 2014 and 2022, seven of them in Korea. Injections showed promising outcomes for wrinkles, texture and elasticity with statistically significant results in several studies — but the authors rated the evidence low to moderate quality, none of the studies achieved full marks on quality appraisal, and the variation in technique and outcome measures made meta-analysis impossible. That is a fair picture: real, encouraging, and not yet settled.

The topical picture changed in late 2025, and most English guides have not caught up. Two developments matter.

The Two Studies That Changed the Answer

Study	What it found	The catch
Peony PDRN Bak et al., IJMS, Dec 2025	A low-molecular-weight PDRN from Paeonia lactiflora — a plant source, not salmon. Topical use cut transepidermal water loss in an SLS-damaged skin model over two weeks (n=10), and periorbital skin elasticity improved after four weeks	Small, single study, on a specific plant-derived low-MW material that is not what most products on the shelf contain. All six authors work for the company that makes it
PDRN-850K eye cream Ye et al., PLOS ONE, Jul 2026	A randomised, double-blind, split-face trial of a 0.1% medium-length PDRN eye cream against an identically formulated 0.1% retinol cream over 28 days. Ultrasound showed roughly double the increase in dermal thickness and density versus retinol; crow's feet area fell about 20–23% against 6–7% for retinol. Penetration was separately assessed by confocal Raman spectroscopy	One 0.1% preparation capped at 850 kDa, in one eye cream, over 28 days, with the material supplied by a biotechnology company. Impressive design; narrow claim

So the honest 2026 answer is not "topical PDRN doesn't work." It is that two specific preparations — one low-MW plant-derived, one medium-length at 850 kDa — now have published human topical data, and the PLOS ONE trial went further than most cosmetic research by measuring penetration rather than assuming it. What has not happened is the thing the marketing implies: none of this transfers to a serum simply because the word "PDRN" is on the box. Molecular weight, source, concentration and formulation are what the evidence attaches to. The ingredient name is not.

Reading the Literature Honestly

Reasonably supported	Still not established
A2A receptor engagement as the mechanism	That an unspecified "PDRN serum" delivers enough to trigger it
Wound healing and anti-inflammatory effects when delivered into tissue	That injectable results transfer to any topical product
Injectable outcomes for wrinkles, texture and elasticity — at low to moderate evidence quality	Long-term topical outcomes; both topical trials ran four weeks
Two named topical preparations, in published human trials	That every product labelled "PDRN" contains a comparable material

Check who funded the study — every time, in this field. The Squadrito review carries a 2022 corrigendum: the conflict-of-interest statement had been filed incorrectly and patent disclaimers were omitted, and the corrected statement records research support from Mastelli, a PDRN manufacturer. The peony study's authors all work at the company developing that ingredient. The PLOS ONE eye-cream material was supplied by a biotechnology firm. None of this makes the findings wrong — industry funds most ingredient research and the alternative is no research at all — but a field this commercially hot rewards reading the funding line before the abstract. We link every paper so you can.

Cross-section diagram of skin contrasting an injectable delivering PDRN into the dermis with a topical serum sitting on the stratum corneum

4. How to read a PDRN label without being fooled

"PDRN" on a box is not a regulated cosmetic claim in most markets, which means the word alone tells you very little — and the 2025–26 trials made that sharper, not softer, because they attached their results to specific materials rather than to the ingredient category. Five questions narrow it down.

Five Questions for Any PDRN Product

Ask	What a good answer looks like
Is it PDRN or PN?	Polynucleotide (PN) is a related but distinct, generally longer-chain material. Brands use the terms loosely; a clear answer signals a serious formulator
What concentration?	A stated percentage. "Contains PDRN" with no figure could mean a trace inclusion added for the ingredient list
Where does it sit in the INCI list?	Near the end means very little is present. This is the check nobody does and it is the most informative one
What molecular weight?	The single most useful question in 2026. The preparations with published topical human data are a low-MW plant-derived PDRN and a medium-length one capped at 850 kDa. A brand that cannot state a molecular weight cannot claim that evidence
Salmon or plant?	Not a quality ranking — a different material. Plant-derived low-MW PDRN is where the first topical clinical data came from, and it is a genuinely separate category from standard salmon PDRN
What is the delivery claim?	Any serious formulation will say something about how it addresses the size problem. Silence on this is the answer

The market context matters too. PDRN reached global attention through Korean dermatology, where injectable use is widespread, and the topical category grew in that slipstream. That is a marketing lineage, not evidence transfer — the serum did not inherit the injectable's trial data by association.

5. The Japan angle: why this is a clinic conversation here

Japan regulates cosmetics, quasi-drugs and pharmaceuticals as three separate tiers, and a topical sold as a cosmetic cannot make a therapeutic claim. That framework is the reason a Japanese drugstore shelf looks conservative next to the claims you see on imported PDRN serums online — not because the ingredient is unavailable, but because the claim would not be permitted on a cosmetic.

Meanwhile the injectable side of regenerative aesthetics is well established in Japanese clinics under private-pay (jiyu shinryo) practice, where consultations are long and the doctor is paid for time rather than a reimbursed procedure code. Our guides to Rejuran and skin boosters in Japan cover that category with prices; Profhilo is the adjacent hyaluronic-acid version.

If You Are Choosing Between Them

Situation	Reasonable move
Curious, low budget, no urgency	A topical is a low-risk experiment. Judge it on comfort and barrier feel, not on promised regeneration
Post-procedure recovery	Ask the clinic that did the procedure. Do not self-prescribe a serum onto healing skin
You want the effect the studies describe	That is the injectable, and it is a physician conversation — not a shopping one
Sensitive or reactive skin	PDRN's anti-inflammatory framing is not a hypoallergenic guarantee. Patch test

Illustration of an INCI ingredient list with a magnifying glass over the position of a PDRN entry near the end of the list

6. Our position

PDRN is a real molecule with real pharmacology and a genuine clinical literature behind it. None of that is hype. And as of 2026, topical PDRN is no longer an evidence-free category either — two named preparations have published human data, and one of them measured penetration rather than assuming it.

What remains hype is the transfer. A 0.1% medium-length PDRN in one eye cream, tested over 28 days, does not tell you what an unspecified salmon-derived serum does. The evidence attaches to a molecular weight, a source, a concentration and a formula — not to a four-letter ingredient name on a box. That distinction is the entire consumer problem, and it is the one the category's marketing is least interested in making.

So: a topical PDRN product is a reasonable thing to try, and more reasonable than it was a year ago. Ask which preparation, at what molecular weight and concentration. If the brand cannot answer, it is selling you the name.

7. What PDRN is competing against

The most useful context for any new ingredient is what it would replace, and the July 2026 trial made this unusually concrete by choosing retinol as its comparator rather than a placebo.

That was a deliberately hard test. Retinol has decades of published evidence for photoaging and is the reference topical active in dermatology — and a 0.1% medium-length PDRN eye cream outperformed an identically formulated 0.1% retinol cream on dermal thickness and crow's feet over 28 days. Taken at face value, that is a meaningful result.

Reading That Comparison Fairly

Point in PDRN's favour	Point against reading too much into it
Comparator was an active with real evidence, not a placebo	28 days is short for retinol, which is generally assessed over months
Identical formulation on both sides — a clean comparison	0.1% is a modest retinol concentration; higher-strength products exist
Penetration measured rather than assumed	One preparation, one formula, one trial, industry-supplied material
Tolerability reported as favourable in sensitive skin	Retinol's known irritation profile is exactly what a 28-day window highlights

One study does not displace a category. Retinoids carry decades of accumulated evidence across many concentrations, formulations and populations. A single well-designed trial of one PDRN preparation against one retinol concentration is a genuine data point, not a replacement. If you already use a retinoid that works for you, this is not a reason to abandon it.

Where the money is better spent

Whatever the ingredient debate resolves to, the ranking of what actually affects skin over years is not seriously contested, and it is worth stating because it puts a ¥10,000 serum in perspective.

Priority Order, Regardless of PDRN

Priority	Why it outranks a novel active
1. Daily sunscreen	The single largest modifiable factor in visible skin ageing. Nothing in a serum competes — see Anessa, Skin Aqua, Biore UV
2. A retinoid, if tolerated	The deepest evidence base of any topical anti-ageing active
3. Barrier support	Unglamorous, cheap, and the thing most damaged skin actually needs
4. Everything else, including PDRN	Worth exploring once the first three are in place. Not a substitute for any of them

For structural change rather than surface support, the honest answer remains the clinic. Our guides to Rejuran, skin boosters and laser treatment in Japan cover what those procedures do and cost — and Japanese private-pay pricing makes several of them cheaper than a year of premium serums.

8. FAQ

What is PDRN in skincare?

Polydeoxyribonucleotide — a mixture of DNA fragments of roughly 50 to 1,500 kDa, purified from the sperm DNA of salmon trout or chum salmon, with proteins and peptides removed. Its proposed mechanism is engaging the adenosine A2A receptor and supplying nucleotides to the cellular salvage pathway. It entered medicine as an injectable wound-healing drug; the cosmetic serum is a later, separate use.

Does topical PDRN actually work?

As of 2026, two specific preparations do. A December 2025 study of low-molecular-weight peony PDRN reported improved periorbital skin elasticity after four weeks of topical use, and a July 2026 randomised, double-blind, split-face trial found a 0.1% medium-length PDRN eye cream outperformed an identically formulated 0.1% retinol cream on dermal thickness and crow's feet over 28 days, with penetration separately measured. Both are small, short, and industry-linked. Neither tells you what an unspecified salmon-derived serum does — the evidence attaches to a molecular weight, source, concentration and formula, not to the ingredient name.

Is PDRN the same as salmon DNA?

Effectively yes as source material. PDRN is purified and fragmented DNA from salmon trout or chum salmon sperm. "Salmon DNA skincare" is the consumer-facing name for the same thing, though the phrase is used loosely enough that it also gets applied to products containing related polynucleotides rather than PDRN specifically.

PDRN or polynucleotides — what's the difference?

They are related materials and brands use the terms interchangeably, but polynucleotide (PN) generally refers to longer-chain material while PDRN denotes the specific fragmented, purified preparation described in the pharmacology literature. If a brand cannot tell you clearly which one is in the bottle, that itself is informative.

How do I tell if a PDRN serum is legitimate?

Check four things: whether it says PDRN or PN, whether a concentration is stated, where the ingredient sits in the INCI list, and whether the brand states a molecular weight. That last one now matters most — the two preparations with published topical human data are a low-molecular-weight plant-derived PDRN and a medium-length one capped at 850 kDa, so a brand that cannot tell you its molecular weight cannot claim any of that evidence. An ingredient near the end of the list with no percentage and no molecular weight is a marketing inclusion.

Should I get PDRN injections instead?

That is a physician question, not a shopping one, and the answer depends on your skin, your goals and what is legally available where you are — regulatory status varies sharply by country. If the effects described in the studies are what you want, injectable delivery is what those studies used. Discuss it with a doctor rather than deciding from an article.

Sources & Method

PDRN's definition, molecular weight range, source species, purification and proposed A2A-receptor mechanism are taken from the peer-reviewed pharmacology literature cited below, not from brand material. This page was substantially revised in August 2026: it previously described topical PDRN as lacking human clinical evidence, which two studies published between December 2025 and July 2026 changed for two specific preparations. We report both, including their funding relationships and their limits, and we link the 2022 corrigendum alongside the 2017 review so the conflict-of-interest correction is visible. We deliberately do not name, rank or price individual PDRN serums: the category is unstandardised and naming products would imply a comparison we have not run. The label-checking framework, the topical-vs-injectable table and our closing position are editorial judgement.

Peer-reviewed literature

Source	Used for
Pharmacological Activity and Clinical Use of PDRN (PMID 28491036) Squadrito et al., Frontiers in Pharmacology, 2017 · peer-reviewed mini-review · accessed 8 Aug 2026	The 50–1,500 kDa range, the Oncorhynchus mykiss and Oncorhynchus keta source species, the purification removing immunogenic proteins and peptides, the A2A receptor mechanism, the salvage pathway, and the diabetic foot ulcer indication
Corrigendum: Pharmacological activity and clinical use of PDRN Squadrito et al., Frontiers in Pharmacology, 2022 · correction notice · accessed 8 Aug 2026	The corrected conflict-of-interest statement and omitted patent disclaimers referenced in section 3, including the disclosed research support from a PDRN manufacturer
Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering Kim et al., Marine Drugs, 2021 · peer-reviewed review · accessed 8 Aug 2026	Corroboration of the molecular weight range and source, and the framing of PDRN's established indications as wound healing and inflammation
The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review (PMID 39645667) Lampridou et al., Journal of Cosmetic Dermatology, 2025 · systematic review · n=219 · accessed 8 Aug 2026	The nine studies covering 219 patients in section 3, the 2014–2022 publication window, seven of nine being Korean, the low-to-moderate quality rating, and the note that variation precluded meta-analysis
Anti-Aging Efficacy of Low-Molecular-Weight Polydeoxyribonucleotide Derived from Paeonia lactiflora Bak et al., International Journal of Molecular Sciences, December 2025 · peer-reviewed · industry-authored · accessed 8 Aug 2026	The first topical human data cited in section 3 — reduced transepidermal water loss in an SLS-damaged model over two weeks (n=10) and improved periorbital elasticity at four weeks. All listed authors are affiliated with the company developing the ingredient, which we flag in the same section
Topical medium-length PDRN enhances dermal extracellular matrix repair in photodamaged skin (PLOS ONE 21(7): e0350905) Ye et al., PLOS ONE, July 2026 · randomised double-blind split-face · accessed 8 Aug 2026	The 0.1% PDRN-850K vs 0.1% retinol split-face comparison over 28 days, the roughly two-fold dermal thickness and density differences on high-frequency ultrasound, the crow's feet figures (≈20–23% vs 6–7%), and the confocal Raman penetration assessment. Material supplied by a biotechnology company, which we flag

Regulatory sources

Source	Used for
Cosmetics and quasi-drugs policy pages Ministry of Health, Labour and Welfare (Japan) · primary · accessed 8 Aug 2026	Japan's three-tier cosmetic / quasi-drug / pharmaceutical structure in section 5, and the principle that a cosmetic cannot carry a therapeutic claim

ClinicJapan editorial

Source	Used for
The molecular-size objection, and its current limits ClinicJapan Research Team · Reasoning from published properties, updated August 2026	Section 2. The barrier argument follows from PDRN's documented molecular weight. We no longer state that no penetration data exists — the PLOS ONE study assessed delivery by confocal Raman spectroscopy for one 850 kDa preparation. We have not found equivalent penetration data for standard salmon-derived PDRN in an ordinary serum, which is the case the objection still applies to
Why we updated this page Editorial note · Revision log · August 2026	This guide originally described topical PDRN as lacking human evidence. Two studies published between December 2025 and July 2026 changed that for two specific preparations, and sections 2, 3 and 6 were rewritten accordingly. Our position on the transfer problem — that evidence attaches to a material, not to an ingredient name — is unchanged
The retinol comparison and the priority ranking ClinicJapan Research Team · Editorial framing of a cited trial · priority order is our own	Section 7. The comparison figures come from the PLOS ONE study cited above; the fair-reading table and the four-step priority order are our editorial position. That sunscreen is the largest modifiable factor in photoageing is general dermatological consensus rather than a finding from any paper cited here
Label-checking framework ClinicJapan Research Team · Editorial method	Section 4 in full. The four questions are our own consumer heuristic, not an industry standard
No products named or ranked Editorial note · Transparency item	Throughout. We take no commission from any PDRN brand and deliberately name none — the category is unstandardised and a product list would imply testing we have not done
Our closing position ClinicJapan Research Team · Editorial opinion	Section 6. Reasonable practitioners disagree about topical PDRN; this is our reading of the current public evidence, not a settled consensus

About this guide: This is an independent guide. We receive no commission from any PDRN brand, clinic, or retailer, and nobody paid to be included. PDRN's regulatory status differs sharply between countries and changes over time — confirm locally. Injectable treatments are medical procedures requiring a qualified physician. Informational only; not medical advice, and not a substitute for consultation with a doctor.

PDRN Skincare: Reading the Evidence Behind Salmon DNA Serums